The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Dasatinib Krka 140 mg film-coated tablets



KRKA, d.d., Novo mestoPA1347/093/006

Main Information

Trade NameDasatinib Krka 140 mg film-coated tablets
Active SubstancesDasatinib
Dosage FormFilm-coated tablet
Licence HolderKRKA, d.d., Novo mesto
Licence NumberPA1347/093/006

Group Information

ATC CodeL01XE06 dasatinib

Status

License statusAuthorised
Licence Issued03/04/2020
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceMedicinal product subject to restricted medical prescription (See: Summary of Product Characteristics, section 4.2)
Marketing StatusNot marketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back